ese type	a plus sign (+) inside this box	->	+

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Complete if Known			
Application Number	10/622,769		
Filing Date	July 21, 2003		
First Named Inventor	Emir		
Group Art Unit	-		
Examiner Name			
Attorney Docket Number	109536.182		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ESO		Shua-Haim et al, Annals of Long-Term Care, Volume 7, No. 2 (February 1999) (5 pages).	
ESO		Pfizer Press Release dated August 30, 2000 (4 pages).	
ESO		Pfizer Press Release dated August 28, 2001 (5 pages).	
ESO		Eisai Press Release dated April 4, 2003 (5 pages).	
ESO		Feldman et al, Neurology, 54(Suppl. 3):A469 (Abstract No. S79.003) (April 2000).	
ESO		Feldman et al, Neurology, 57:613-620 (2001).	
ESO		The Pharmaceutical Journal, 267:376 (September 22, 2001).	
ESO		Burns et al, Dementia and Geriatric Cognitive Disorders, 10:237-244 (1999).	
ESO		Gautheir et al, International Psychogeriatrics, 14(4):389-404 (December 2002).	
ESO		Geldmacher, Comprehensive Therapy, 23(7):492-493 (1997).	
ESO		Rogers et al, Arh. Intern. Med., 158:1021-1031 (1998).	

Examiner	/Rud = 01 /	Date	27/24/222
Signature	/Eric Olson/	Considered	05/04/2006

^{*}EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.

Please type	a plus sign	(+) inside this	box →	+

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE action of information unless it contains a valid OMB control company.

Under the Paperwork Reduction Act of 1995, no persons are required to respond

Sheet

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USO as many	2110012 (as necessary
2	of	2

to a conscion of internation and so it contains a value of the control fluttings.			
Complete if Known			
Application Number	10/622,769		
Filing Date	July 21, 2003		
First Named Inventor	Emir		
Group Art Unit			
Examiner Name			
Attorney Docket Number	109536.182		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Perry et al, The Lancet, page 189 (January 22, 1977).	
ESO			
ESO		Homma et al, Dementia and Geriatric Cognitive Disorders, 11:299-313 (2000).	
ESO		Doody, Gerontology, 45(suppl. 1):23-32 (1999).	
ESO		Doody et al, Arch. Neurol., 58:427-433 (March 2001).	
ESO		Onofrj et al, Clinical Neuropharmacology, 25(4):207-215 (2002).	
-			
			

Examiner	/Eric Olson/	Date	
Signature	/Bilc Oibon/	Considered	05/04/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SHEET 1 OF

ATTY. DOCKET NO. SERIAL NO. 109536.182 unassigned INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) APPLICANT Birol EMIR et al. FILING DATE GROUP Herewith **U.S. PATENT DOCUMENTS** EXAMINER'S FILING INITIALS PATENT NO. CLASS SUBCLASS DATE NAME DATE **FOREIGN PATENT DOCUMENTS EXAMINER'S** DATE COUNTRY **CLASS SUBCLASS** PATENT NO. INITIALS Yes No OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Shua-Haim, J. R., MD, FACP, AGSF, Vered Shua-Haim, RN, BSN, Mildred Sabo, MD and J. S. Ross, MD, FACP, AGSF, "Case Report: Donepezil in the Treatment of Advanced Alzheimer's Disease," Volume 7, **ESO** Number 2, February 1999, 5 pages. DATE CONSIDERED **EXAMINER** /Eric Olson/ 05/02/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.